To develop a genetic risk model for primary myelodysplastic syndromes (MDS), we queried the prognostic significance of next-generation sequencing (NGS)-derived mutations, in the context of the Mayo cytogenetic risk stratification, which includes high-risk (monosomal karyotype; MK), intermediate-risk (non-MK, classified as intermediate/poor/very poor, per the revised international prognostic scoring system; IPSS-R), and low-risk (classified as good/very good, per IPSS-R). Univariate analysis in 300 consecutive patients with primary MDS identified TP53, RUNX1, U2AF1, ASXL1, EZH2, and SRSF2 mutations as "unfavorable" and SF3B1 as "favorable" risk factors for survival; for the purposes of the current study, the absence of SF3B1 mutation was accordingly dubbed as an "adverse" mutation. Analysis adjusted for age and MK, based on our previous observation of significant clustering between MK and TP53 mutations, confirmed independent prognostic contribution from RUNX1, ASXL1, and SF3B1 mutations. Multivariable analysis that included age, the Mayo cytogenetics risk model and the number of adverse mutations resulted in HRs (95% CI) of 5.3 (2.5-10.3) for presence of three adverse mutations, 2.4 (1.6-3.7) for presence of two adverse mutations, 1.5 (1.02-2.2) for presence of one adverse mutation, 5.6 (3.4-9.1) for high-risk karyotype, 1.5 (1.1-2.2) for intermediate-risk karyotype and 2.4 (1.8-3.3) for age >70 years; HR-weighted risk point assignment generated a three-tiered genetic risk model: high (N 5 65; 5-year survival 2%), intermediate (N 5 100; 5-year survival 18%), and low (N 5 135; 5-year survival 56%). The current study provides a practically simple risk model in MDS that is based on age, karyotype, and mutations only.
| I N TR ODU C TI ON
Myelodysplastic syndromes (MDS) constitute a preleukemic state of clonal hematopoiesis that is currently diagnosed by bone marrow (BM) morphologic criteria.
1,2 MDS-associated excess mortality accounts for the majority of deaths 3 and survival has not improved over the last several decades. 4 At present, allogeneic hematopoietic stem cell transplant (HCT) remains the only treatment modality in MDS that can offer the chance of cure or prolonged survival, 5 although otherwise long-lived patients can be identified by their ability to achieve chemotherapyinduced complete remission. 6 Unfortunately, HCT entails substantial treatment-related mortality and morbidity, which necessitates accurate selection of patients in whom such risk is justified. In 2012, IPSS was revised into the practically more complicated IPSS-R. 8 Components of IPSS-R were similar to that of IPSS but further /L), and cytogenetic abnormalities. ; one or more mutations were detected in more than 80% of the patients with the most frequent being ASXL1 (30%), TET2 (25%),
IPSS-R considers five cytogenetic categories: very good (-Y
and DNMT3A (10%). The particular study identified ASXL1, SETBP1, and TP53 as age-and inter-independent predictors of inferior survival, SF3B1 as predictor of favorable survival and SRSF2, IDH2, and CSF3R
as predictors of leukemic transformation. 17 However, the inclusion of risk stratification by IPSS-R resulted in loss of significance for TP53 and SF3B1 mutations. 17 In a subsequent study, 18 we found significant clustering of TP53 Based on our previous observations regarding the questionable value of "missense" ASXL1 mutations in chronic myelomonocytic leukemia (CMML), 22 and after confirmation of its lack of significant prognostic contribution in the current MDS series, we only considered frameshift or nonsense ASXL1 mutations for survival analysis. Figure 1C) . 13 For the sake of uniformity, the Mayo low-risk cytogenetic group included the IPSS-R good and very good cytogenetic risk categories ( Figure 1C ). Supporting Information which led to higher utilization of disease-modifying therapy (P 5 .0034).
| Mutations and karyotype
Recurrently mutated genes included SF3B1 30%, ASXL1 27%, TET2
23%, U2AF1 14%, DNMT3A 13%, SRSF2 13%, TP53 12%, RUNX1 10%, IDH2 4% and 3% each for EZH2, SETBP1, IDH1, CSF3R, CEBPA, and 
| Mutations and survival
At a median follow up of 19 months, 203 deaths (68%) and 31 (10%) leukemic transformations were recorded. In univariate analysis, TP53
(P 5 .0006; HR 2.2), RUNX1 (P 5 .0005, HR 2.4), U2AF1 (P 5 .003, HR 1.9), ASXL1 (P 5 .02, HR 1.5), EZH2 (P 5 .03; HR 2.3), and SRSF2 (P 5 .04; HR 1.6) mutations were found to be "unfavorable" and SF3B1 (P < .0001; HR 0.5) "favorable" risk factors for survival (Supporting Information Table S2 ). For the purposes of the current study, the absence of SF3B1 mutation was accordingly dubbed as the presence of an "adverse" mutation. (27) 1 (3) 28 (36) 52 (27) .0005 TET2 mutated; n (%) 68 (23) 4 (13) 13 (17) 51 (27) .08 U2AF1 mutated; n (%) 42 (14) 2 (6) 24 (31) 16 (8) <.0001 DNMT3A mutated; n (%) 40 (13) 6 (19) 9 (12) 25 (13) .6 SRSF2 mutated; n (%) 38 (13) 0 (0) 16 (21) 22 (12) .005 TP53 mutated; n (%) 37 (12) 25 (78) 4 (5) 8 (4) <.0001 RUNX1 mutated; n (%) 29 (10) 1 (3) 13 (17) 15 (8) .04
.06 
| D ISC USSION
The current study provides proof-of-principle regarding the feasibility of genetics-based risk stratification in MDS. Towards that end, our study highlights the importance of clarifying the prognostic interaction between karyotype and mutations and their inter-independent value in a genetics-based prognostic model. The unique association between TP53 mutations and MK was again confirmed in the current study. The prognostic contribution of RUNX1 mutations in MDS and their occurrence both early in the disease and their acquisition during the disease course has been recognized for over a decade now. 23 In contrast, ASXL1 and SF3B1 mutations in MDS are rarely acquired during the disease course. 24, 25 Our observations regarding the prognostic relevance of these two latter mutations are supported by most but not all other previously published reports. 16, [25] [26] [27] The same can be said regarding other mutations found to be prognostically relevant in other studies (e.g. TET2) 28 but not in the current study. 16, 29 In one of the most recent studies that explored the integration of molecular data with clinical risk models, univariate analysis identified TP53, RUNX1,EZH2, and NPM1 mutations as being unfavorable and SF3B1 mutations as being favorable for survival. 27 However, during multivariable analysis that included age and several clinical risk models, only TP53, EZH2, and SF3B1 retained their significance. 27 Regardless, the main objective of the current study was not to reconcile differences between studies regarding prognostic relevance of mutations in MDS, but to highlight the impact of karyotype on prognostic relevance of specific mutations. Based on our observations, we doubt an MK-independent prognostic contribution of TP53 mutations in MDS. Accordingly, prognostic relevance of mutations in MDS should be re-visited after proper accounting for karyotype, and especially for the presence or absence of MK. [30] [31] [32] [33] Equally important for moving forward with disease prognostication in MDS is to avoid making matters more complicated than they already are, in terms of utility in routine clinical practice. We believe that our new genetics-based risk model effectively addresses the latter issue.
A few limitations of our study include a relatively sample size to study the co-occurrence of mutations given that MDS is a heterogenous disease entity and that variant allele frequencies were not considered in our analysis. Finally, our study highlights the prognostic value of age in MDS, despite the fact that it is currently not included in IPSSR; other recent studies have arrived at the same conclusion. 
